IGF2 and colorectal carcinoma: Finally, we analysed samples from 147 additional CRC patients that were excluded from the survival analysis and found no differences in their PBL IGF2 methylation levels compared to those of the 281 CRC patients included in the survival analysis (Supplementary Table 8).